



## PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-28	114	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

### Description

The global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the PMO (Phosphorodiamidate Morpholino Oligomers) Drug market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the PMO (Phosphorodiamidate Morpholino Oligomers) Drug market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the PMO (Phosphorodiamidate Morpholino Oligomers) Drug market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of PMO (Phosphorodiamidate Morpholino Oligomers) Drug include Avidity Biosciences, Dyne, Nippon Shinyaku, NS Pharma, Inc. and Sarepta Therapeutics, Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

### Report Scope

This report quantifies the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to PMO (Phosphorodiamidate Morpholino Oligomers) Drug.

### Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Company

Avidity Biosciences

Dyne

Nippon Shinyaku

NS Pharma, Inc.

Sarepta Therapeutics, Inc

### **PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Type**

DMD exon 45 Based

DMD exon 51 Based

DMD exon 53 Based

Other

### **PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Application**

Hospital

Clinic

### **PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Region**

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

### **Key Drivers & Barriers**

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks

on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## **Reasons to Buy This Report**

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PMO (Phosphorodiamidate Morpholino Oligomers) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## **Chapter Outline**

### **Chapter 1:**

Research objectives, research methods, data sources, data cross-validation;

### **Chapter 2:**

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

### **Chapter 3:**

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

### **Chapter 4:**

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

### **Chapter 5:**

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

### **Chapter 6:**

Detailed analysis of PMO (Phosphorodiamidate Morpholino Oligomers) Drug companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its

main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

**Chapter 12:**

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

**Chapter 13:**

The main points and conclusions of the report.

# Table of Contents

---

## 1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

---

## 2 Market Overview

- 2.1 Product Definition
- 2.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Type
  - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  - 2.2.2 DMD exon 45 Based
  - 2.2.3 DMD exon 51 Based
  - 2.2.4 DMD exon 53 Based
  - 2.2.5 Other
- 2.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Application
  - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  - 2.3.2 Hospital
  - 2.3.3 Clinic
- 2.4 Assumptions and Limitations

---

## 3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Breakdown Data by Type

- 3.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Historic Market Size by Type (2021-2026)
- 3.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecasted Market Size by Type (2027-2032)

---

## 4 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Breakdown Data by Application

- 4.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Historic Market Size by Application (2021-2026)
- 4.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecasted Market Size by Application (2027-2032)

---

## 5 Global Growth Trends

- 5.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Perspective (2021-2032)
- 5.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Growth Trends by Region
  - 5.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region: 2021 VS 2025 VS 2032
  - 5.2.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Historic Market Size by Region (2021-2026)
  - 5.2.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecasted Market Size by Region (2027-2032)
- 5.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Dynamics
  - 5.3.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends
  - 5.3.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Drivers
  - 5.3.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Challenges
  - 5.3.4 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Restraints

---

## 6 Market Competitive Landscape by Players

- 6.1 Global Top PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players by Revenue
  - 6.1.1 Global Top PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players by Revenue (2021-2026)

- 6.1.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Players (2021-2026)
  - 6.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Players Ranking, 2023 VS 2024 VS 2025
  - 6.3 Global Key Players of PMO (Phosphorodiamidate Morpholino Oligomers) Drug Head Office and Area Served
  - 6.4 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players, Product Type & Application
  - 6.5 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Manufacturers Established Date
  - 6.6 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market CR5 and HHI
  - 6.7 Global Players Mergers & Acquisition
- 

## 7 North America

- 7.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
  - 7.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  - 7.3 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  - 7.4 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032)
  - 7.5 United States
  - 7.5 United States
  - 7.6 Canada
  - 7.7 Mexico
- 

## 8 Europe

- 8.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
  - 8.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  - 8.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  - 8.4 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032)
  - 8.5 Germany
  - 8.6 France
  - 8.7 U.K.
  - 8.8 Italy
  - 8.9 Spain
  - 8.10 Russia
  - 8.11 Netherlands
  - 8.12 Nordic Countries
- 

## 9 Asia-Pacific

- 9.1 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
  - 9.2 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  - 9.3 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
  - 9.4 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032)
  - 9.5 China
  - 9.6 Japan
  - 9.7 South Korea
  - 9.8 India
  - 9.9 Australia
  - 9.10 China Taiwan
  - 9.11 Southeast Asia
- 

## 10 South America

- 10.1 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
- 10.2 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

10.3 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)

10.4 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032)

10.5 Brazil

10.6 Argentina

10.7 Chile

10.8 Colombia

10.9 Peru

---

## 11 Middle East & Africa

11.1 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)

11.2 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

11.3 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)

11.4 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032)

11.5 Saudi Arabia

11.6 Israel

11.7 United Arab Emirates

11.8 Turkey

11.9 Iran

11.10 Egypt

---

## 12 Players Profiled

12.1 Avidity Biosciences

12.1.1 Avidity Biosciences Company Information

12.1.2 Avidity Biosciences Business Overview

12.1.3 Avidity Biosciences Revenue in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026)

12.1.4 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio

12.1.5 Avidity Biosciences Recent Developments

12.2 Dyne

12.2.1 Dyne Company Information

12.2.2 Dyne Business Overview

12.2.3 Dyne Revenue in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026)

12.2.4 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio

12.2.5 Dyne Recent Developments

12.3 Nippon Shinyaku

12.3.1 Nippon Shinyaku Company Information

12.3.2 Nippon Shinyaku Business Overview

12.3.3 Nippon Shinyaku Revenue in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026)

12.3.4 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio

12.3.5 Nippon Shinyaku Recent Developments

12.4 NS Pharma, Inc.

12.4.1 NS Pharma, Inc. Company Information

12.4.2 NS Pharma, Inc. Business Overview

12.4.3 NS Pharma, Inc. Revenue in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026)

12.4.4 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio

12.4.5 NS Pharma, Inc. Recent Developments

12.5 Sarepta Therapeutics, Inc

12.5.1 Sarepta Therapeutics, Inc Company Information

12.5.2 Sarepta Therapeutics, Inc Business Overview

12.5.3 Sarepta Therapeutics, Inc Revenue in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026)

12.5.4 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio

12.5.5 Sarepta Therapeutics, Inc Recent Developments

---

## **13 Report Conclusion**

---

## **14 Disclaimer**

## List of Tables and Figures

---

### List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Type (2021-2026)
- Table 7: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Type (2027-2032)
- Table 9: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Application (2021-2026)
- Table 11: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Application (2027-2032)
- Table 13: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region (2021-2026)
- Table 16: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region (2027-2032)
- Table 18: PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends
- Table 19: PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Drivers
- Table 20: PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Opportunities and Challenges
- Table 21: PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Restraints
- Table 22: Global Top PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Players (2021-2026)
- Table 24: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of PMO (Phosphorodiamidate Morpholino Oligomers) Drug, Headquarters and Area Served
- Table 26: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth Rate by Country: 2021 VS

2025 VS 2032 (US\$ Million)

- Table 40: South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Avidity Biosciences Company Information
- Table 46: Avidity Biosciences Business Overview
- Table 47: Avidity Biosciences Revenue in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026) & (US\$ Million)
- Table 48: Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
- Table 49: Avidity Biosciences Recent Developments
- Table 50: Dyne Company Information
- Table 51: Dyne Business Overview
- Table 52: Dyne Revenue in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026) & (US\$ Million)
- Table 53: Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
- Table 54: Dyne Recent Developments
- Table 55: Nippon Shinyaku Company Information
- Table 56: Nippon Shinyaku Business Overview
- Table 57: Nippon Shinyaku Revenue in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026) & (US\$ Million)
- Table 58: Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
- Table 59: Nippon Shinyaku Recent Developments
- Table 60: NS Pharma, Inc. Company Information
- Table 61: NS Pharma, Inc. Business Overview
- Table 62: NS Pharma, Inc. Revenue in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026) & (US\$ Million)
- Table 63: NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
- Table 64: NS Pharma, Inc. Recent Developments
- Table 65: Sarepta Therapeutics, Inc Company Information
- Table 66: Sarepta Therapeutics, Inc Business Overview
- Table 67: Sarepta Therapeutics, Inc Revenue in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026) & (US\$ Million)
- Table 68: Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
- Table 69: Sarepta Therapeutics, Inc Recent Developments
- Table 70: Authors List of This Report

### List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Image
- Figure 5: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Type: 2025 VS 2032
- Figure 7: DMD exon 45 Based Product
- Figure 8: DMD exon 51 Based Product
- Figure 9: DMD exon 53 Based Product
- Figure 10: Other Product
- Figure 11: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 12: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Application: 2025 VS 2032
- Figure 13: Hospital Product
- Figure 14: Clinic Product
- Figure 15: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 16: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 17: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region: 2025 VS 2032

- Figure 18: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Players in 2025
- Figure 19: Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Manufacturers Established Date
- Figure 20: Global Top 5 and 10 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Market Share by Revenue in 2025
- Figure 21: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 22: North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 23: North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032)
- Figure 24: United States PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 25: Canada PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 26: Mexico PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032)
- Figure 27: Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 28: Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032)
- Figure 29: Germany PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 30: France PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 31: U.K. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: Italy PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 33: Spain PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: Russia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: Netherlands PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Nordic Countries PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032)
- Figure 39: China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 40: Japan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: South Korea PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: India PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: India PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032)
- Figure 44: Australia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 45: China Taiwan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Country (2021-2032)
- Figure 49: Brazil PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 50: Argentina PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: Chile PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: Colombia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 53: Peru PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Avidity Biosciences Revenue Growth Rate in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026)
- Figure 55: Dyne Revenue Growth Rate in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026)
- Figure 56: Nippon Shinyaku Revenue Growth Rate in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026)
- Figure 57: NS Pharma, Inc. Revenue Growth Rate in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026)

• Figure 58: Sarepta Therapeutics, Inc Revenue Growth Rate in PMO (Phosphorodiamidate Morpholino Oligomers) Drug Business (2021-2026)